LSCM
PCRX icon

LaSalle Street Capital Management’s Pacira BioSciences PCRX Stock Holding History

LaSalle Street Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$257K Hold
6,748
– – 0.3% 80
2019
Q2 		$293K Sell
6,748
-50
-0.7% -$2.12K 0.34% 73
2019
Q1 		$259K Sell
6,798
-37
-0.5% -$1.44K 0.3% 81
2018
Q4 		$294K Buy
+6,835
New +$319K 0.42% 75

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LaSalle Street Capital Management's PCRX Position: Q3 2019 in Review

LaSalle Street Capital Management held its Pacira BioSciences (PCRX) position steady in Q3 2019 at 6,748 shares worth $257K. The position accounts for 0.3% of the portfolio, ranked #80.

LaSalle Street Capital Management first reported a position in PCRX in Q4 2018 and has held it in 4 quarters since. The position peaked at $294K in Q4 2018. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

  • LaSalle Street Capital Management held 6,748 shares of Pacira BioSciences worth $257K as of Q3 2019.
  • LaSalle Street Capital Management left its Pacira BioSciences share count unchanged in Q3 2019.
  • Pacira BioSciences made up 0.3% of LaSalle Street Capital Management's portfolio in Q3 2019, its #80 holding.
  • LaSalle Street Capital Management first reported a position in Pacira BioSciences in Q4 2018 and has held it in 4 quarters since.
  • LaSalle Street Capital Management's Pacira BioSciences position peaked at $294K in Q4 2018.
  • 211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on LaSalle Street Capital Management's 13F filing for Q3 2019, filed 28 Oct 2019.